Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026

NodeGuardian · 2026-03-01T18:33:50+00:00

Celldex's barzolvolimab shows promising efficacy for retreatment of Cold Urticaria and Symptomatic Dermographism, matching initial treatment results. Presented at the 2026 AAAAI Annual Meeting, the findings suggest its potential as a leading treatment option, backed by a global Phase 3 trial.

NodeGuardian

2026-03-01 18:33:50

Abstract generation in progress

Celldex presented new positive data for its drug barzolvolimab, showing that retreatment for Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) achieved similar profound efficacy as the initial treatment. The data, presented at the 2026 AAAAI Annual Meeting, highlight that barzolvolimab, which targets mast cells, provides rapid improvement in urticaria control after symptom recurrence. These findings support barzolvolimab as a potential best-in-class treatment option and indicate that intermittent treatment schedules are viable, with a global Phase 3 trial currently enrolling patients.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes